COVID-19 Phase III Trial Design: Big Ambitions, Little Consistency
As remdesivir’s change in primary endpoint illustrates, there are many ways to measure potential treatments. A Pink Sheet analysis of 50 Phase III clinical trial protocols found numerous different approaches. Adaptive trials seems critical for speed, but a survival endpoint seems essential for durability.
You may also be interested in...
The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.
“We still try hard to get people to have a control group,” Bob Temple says in an interview. “Not everybody always wants to have a control group. We've been trying hard to do it.”
Final guidance on COVID-19 treatment development emphasizes need for clinical endpoints to reflect drug mechanism, patient population, clinical setting and fast-evolving standard of care – with a cautious embrace of platform and adaptive designs.